Ipsen

Founded in 1929, Ipsen is a global biopharmaceutical group with its headquarters in Boulogne-Billancourt, France. The company's priorities are centered around two main business segments. The first is Specialty Care, which delves into the treatment of complex diseases in specialized fields like oncology, neuroscience, and rare diseases. The second segment is Consumer Healthcare, which targets the broader market by offering over-the-counter medications and health products to consumers. Ipsen's portfolio boasts several important brands that have earned recognition across the healthcare industry. Among them, Somatuline, Decapeptyl, Dysport, NutropinAq, Smecta, and Tanakan stand out, each catering to different therapeutic needs. Additionally, through a partnership with Exelixis, Ipsen extends its oncology presence with Cabometyx. The company's products and services have a vast reach, being sold worldwide with a significant market presence in Europe and North America. Beyond these established markets, Ipsen is actively increasing its market share in emerging economies, with a notable expansion in China. (Powered by AI)